Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALRNNASDAQ:CNSPNASDAQ:CPIXNYSE:LCI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALRNAileron Therapeutics$2.52$1.61▼$4.40$45.72M2.2481,731 shs63,385 shsCNSPCNS Pharmaceuticals$0.88+5.0%$1.03$0.73▼$148.00$4.80M2.65701,680 shs240,222 shsCPIXCumberland Pharmaceuticals$2.60-3.0%$4.92$1.04▼$7.25$38.90M-0.29871,271 shs105,048 shsLCILannett$1.54$0.64▼$3.72$7.38M0.9592,067 shs280,600 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALRNAileron Therapeutics0.00%0.00%0.00%0.00%-27.49%CNSPCNS Pharmaceuticals+5.02%+14.01%-16.29%-32.38%-99.38%CPIXCumberland Pharmaceuticals-2.99%-40.23%-55.48%-41.04%+71.05%LCILannett0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALRNAileron TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACNSPCNS Pharmaceuticals1.503 of 5 stars3.32.00.00.01.60.00.6CPIXCumberland Pharmaceuticals0.556 of 5 stars0.03.00.00.02.31.70.0LCILannettN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALRNAileron Therapeutics 0.00N/AN/AN/ACNSPCNS Pharmaceuticals 2.50Moderate Buy$25.002,744.14% UpsideCPIXCumberland Pharmaceuticals 0.00N/AN/AN/ALCILannett 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest LCI, CPIX, ALRN, and CNSP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025CNSPCNS PharmaceuticalsAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALRNAileron TherapeuticsN/AN/AN/AN/A$1.41 per shareN/ACNSPCNS PharmaceuticalsN/AN/AN/AN/A$5.37 per shareN/ACPIXCumberland Pharmaceuticals$37.87M1.03$0.26 per share10.11$1.61 per share1.61LCILannett$340.58M0.00N/AN/A($23.34) per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALRNAileron Therapeutics-$15.73M-$3.120.00N/AN/AN/A-74.08%-27.93%N/ACNSPCNS Pharmaceuticals-$14.86M-$3,748.50N/A∞N/AN/A-385.41%-193.20%8/13/2025 (Estimated)CPIXCumberland Pharmaceuticals-$6.48M-$0.25N/A∞N/A-7.98%6.92%2.33%8/5/2025 (Estimated)LCILannett-$231.62M-$18.88N/AN/AN/A-62.40%N/A-13.39%N/ALatest LCI, CPIX, ALRN, and CNSP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025CNSPCNS PharmaceuticalsN/A-$1.58N/A-$1.58N/AN/A5/6/2025Q1 2025CPIXCumberland PharmaceuticalsN/A$0.15N/A$0.08N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALRNAileron TherapeuticsN/AN/AN/AN/AN/ACNSPCNS PharmaceuticalsN/AN/AN/AN/AN/ACPIXCumberland PharmaceuticalsN/AN/AN/AN/AN/ALCILannettN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALRNAileron TherapeuticsN/A3.303.30CNSPCNS PharmaceuticalsN/A4.944.94CPIXCumberland Pharmaceuticals0.181.251.09LCILannettN/A2.231.39Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALRNAileron Therapeutics90.89%CNSPCNS Pharmaceuticals14.02%CPIXCumberland Pharmaceuticals15.51%LCILannett40.28%Insider OwnershipCompanyInsider OwnershipALRNAileron Therapeutics5.10%CNSPCNS Pharmaceuticals0.07%CPIXCumberland Pharmaceuticals44.85%LCILannett13.12%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALRNAileron Therapeutics921.67 million20.56 millionNot OptionableCNSPCNS Pharmaceuticals55.46 million5.46 millionNot OptionableCPIXCumberland Pharmaceuticals8014.96 million8.25 millionOptionableLCILannett81010.77 million9.35 millionOptionableLCI, CPIX, ALRN, and CNSP HeadlinesRecent News About These CompaniesDespite Recent Weak Spots, LCI Industries Is Still Appealing At Current PricesJanuary 17, 2025 | seekingalpha.comCompleting a successful tech transferAugust 16, 2024 | pharmaphorum.comPThe pharma trends leading to higher demand for CDMOsAugust 10, 2024 | pharmaphorum.comPLevothyroxine Dosage and the Limitations of Current Bioequivalence StandardsApril 7, 2024 | medscape.comM‘We lost a good friend;’ Coweta County deputy ran over, killed by Alabama officer identifiedJanuary 6, 2024 | wsbradio.comWInsider Traders Made Easy Money on Stock OfferingsOctober 2, 2023 | tradersmagazine.comTLucky Core Industries Ltd.September 20, 2023 | wsj.comLannett (LCI) Stock Sinks on Lowered Guidance, Canaccord DowngradeSeptember 15, 2023 | thestreet.comGeneric-Drugs Antitrust Case Expanded to Include 18 CompaniesAugust 2, 2023 | courthousenews.comCLannett official: Bankruptcy won’t affect Seymour facilityMay 12, 2023 | tribtown.comTLannett official: Bankruptcy won't affect Seymour facility - Seymour TribuneMay 12, 2023 | news.google.comNSocietal CDMO Reports First Quarter 2023 Financial Results - Yahoo FinanceMay 11, 2023 | news.google.comNLannett files prepackaged Chapter 11 cases - Drug Store NewsMay 11, 2023 | news.google.comNVolunteers complete projects for Jackson County United Way’s 27th ... - Seymour TribuneMay 10, 2023 | news.google.comNAround the nation: Biden administration warns against medical ... - The Daily BriefingMay 9, 2023 | news.google.comNGlobal Methylphenidate Drug Market Size Emerging Trends and Will ... - Cottonwood Holladay JournalMay 9, 2023 | news.google.comNGlobal Drugs of UDCA Market Size Analysis, Share, Application ... - The Northwestern ExaminerMay 8, 2023 | news.google.comNErgocalciferol Market Statistical Forecast, Trade Analysis 2023 - Sanofi S.A., Orit Laboratories LLC, Lannett - openPRMay 8, 2023 | news.google.comNGeneric Drugmaker Lannett Hits Ch. 11 With $700M In Debt - Law360May 5, 2023 | news.google.comNPadagis Achieves A US First With Budesonide Foam Launch - Generics BulletinMay 5, 2023 | news.google.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLCI, CPIX, ALRN, and CNSP Company DescriptionsAileron Therapeutics NASDAQ:ALRNAileron Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Austin, Texas.CNS Pharmaceuticals NASDAQ:CNSP$0.88 +0.04 (+5.02%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$0.87 -0.01 (-1.14%) As of 06/27/2025 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.Cumberland Pharmaceuticals NASDAQ:CPIX$2.60 -0.08 (-2.99%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$2.64 +0.04 (+1.50%) As of 06/27/2025 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.Lannett NYSE:LCILannett Co., Inc. engages in the development, manufacture, marketing, and distribution of generic pharmaceutical products. It offers products in different forms including capsules, tablets, liquids, powders, and sprays. The company was founded in 1942 and is headquartered in Trevose, PA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Broadcom’s Big VMware Update: A Threat to Public Cloud Giants? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
